Infants diagnosed with acute myeloid leukemia (AML) frequently harbor cytogenetically cryptic fusions involving KMT2A, NUP98 or GLIS2. Those with AML driven specifically by CBFA2T3::GLIS2 fusions have a dismal prognosis and are currently risk-stratified to receive hematopoietic stem cell transplantation (HSCT) in first remission. Here we report an infant with AML who was refractory to multiple lines of chemotherapy but lacked an identifiable fusion despite cytogenetic, fluorescence in situ hybridization (FISH) and targeted next generation sequencing (NGS) testing. Research-grade RNASeq from a relapse sample revealed in-frame CBFA2T3::GLIS3 and GLIS3::CBFA2T3 fusions. A patient-derived xenograft (PDX) generated from this patient has a short latency period and represents a strategy to test novel agents that may be effective in this aggressive subtype of AML. This report describes the first case of AML with a CBFA2T3::GLIS3 fusion and highlights the need for unbiased NGS testing including RNASeq at diagnosis, as patients with CBFA2T3::GLIS3 fusions should be considered for HSCT in first remission.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528968 | PMC |
| http://dx.doi.org/10.1101/mcs.a006220 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacokinetic analysis of crushed venetoclax tablets combined with azacitizine for recurrent pediatric acute myeloid leukemia (AML).
Cancer Chemother Pharmacol
December 2024
Department of Hematology / Oncology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Background: The efficacy of a combination therapy consisting of venetoclax (VEN) and azacytidine (AZA) for newly diagnosed acute myeloid leukemia (AML) has been confirmed in elderly patients. However, the clinical data on VEN for pediatric AML are limited. A combination therapy consisting of crushed VEN tablets and AZA (VEN/AZA) was administered to two children with recurrent AML.
View Article and Find Full Text PDFClinical significance of dynamic monitoring of EVI1 gene expression in pediatric acute myeloid leukemia.
BMC Pediatr
December 2024
Department of Hematology, Children's Medical Institute of Hematology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, 430016, China.
Objective: To investigate the clinical significance of dynamic monitoring ecotropic virus integration site-1 (EVI1) expression in childhood acute myeloid leukemia (AML).
Methods: A retrospective analysis was conducted on 113 pediatric AML patients of Wuhan Children's Hospital from 2014 to 2022. The correlation between EVI1 expression levels and clinical indicators including clinical characteristics, first complete remission (CR1), relapse, and overall survival (OS) was analyzed.
Bloodstream Infections in Childhood Acute Myeloid Leukemia and Machine Learning Models: A Single-institutional Analysis.
J Pediatr Hematol Oncol
January 2025
Department of Pediatric Hematology/Oncology, Children's Minnesota.
Article Synopsis
- The study examined the use of machine learning (ML) to predict bloodstream infections (BSIs) in children with acute myeloid leukemia (AML) who underwent intensive chemotherapy at Children's Minnesota from 2005 to 2019.
- Over half (54.7%) of the 95 AML patients experienced BSIs, with higher doses of the chemotherapy drug cytarabine increasing the risk, while levofloxacin-vancomycin prophylaxis significantly reduced it.
- The best ML model utilized was regularized logistic regression, which showed a predictive ability better than traditional methods based on neutropenia and fever, highlighting the potential of ML in clinical settings to manage sensitivity and specificity for BSI diagnosis.
Characterization of Pediatric Acute Myeloid Leukemia With t(7;12)(q36;p13).
Genes Chromosomes Cancer
November 2024
Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
Article Synopsis
- Acute myeloid leukemia (AML) with the t(7;12) translocation is common in infants and has been recognized by the WHO, although the exact mechanism behind its development is unclear.
- A study of 12 pediatric AML cases with this translocation found no significant difference in survival rates compared to other AML types, but noted a consistent high expression of MNX1 across all cases.
- Whole transcriptome and genome sequencing revealed various fusion transcripts, primarily involving NOM1, but emphasized the importance of MNX1's overexpression as the key driving factor in this AML subtype.
-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy.
J Immunother Cancer
October 2024
National Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland, USA
Lineage switch (LS) refers to the immunophenotypic transformation of one leukemia lineage to another (ie, lymphoid to myeloid) with retention of baseline genetics. This phenomenon was originally observed in infants with B-lymphoblastic leukemia (B-ALL) with rearrangements following chemotherapy, but is now increasingly being observed as a form of immune escape following targeted therapies among children and adults with B-ALL with and without rearrangements. In this report, we present two cases of adolescents with B-ALL harboring rearrangements (Philadelphia-like phenotype) who developed LS to acute myeloid leukemia following CD19 targeted therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!